BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Joseph Tucker, Chief Executive Officer and Director of Enveric ...

The industry is on a strong growth trajectory, with experts predicting notable achievements over the next decade. Forecasts ...

The Philadelphia market has gained recognition not only for its cell and gene therapy sector but also its real estate scene and talent pool. Vittoria Biotherapeutics, Interius BioTherapeutics and ...

The creature is being trafficked across Africa and Asia to fuel a steady demand for their scales, an ingredient in unproven ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

President Donald Trump said he would likely impose tariffs on automobile, semiconductor and pharmaceutical imports of around ...

Plus: A shift in bird flu strategy, a new vaccine for meningococcal disease, a new AI genomics model from Nvidia and more.

Amicus Therapeutics has two products in the market that generated more than $528 million in revenue last year.

Healthcare costs and spending have been rising in the US. The Centers for Medicare & Medicaid Services reported that ...